Emerging Trends to Reshape the Cardiovascular Clinical Trials Market: Cereno Scientific Partners With CRO For Phase I Study as a Key Influencer

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Cardiovascular Clinical Trials Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for cardiovascular clinical trials has sizeably increased over the recent years. A surge from $5.34 billion in 2024 to $5.73 billion in 2025, at a compound annual growth rate (CAGR) of 7.4%, is projected. The growth experienced in the historical period can be credited to aspects like a rise in myocardial infarction cases, enhanced regulatory environment, burgeoning disease burden, genomics advancements, and heightened need for the development of new drugs.

Cardiovascular Clinical Trials Market Size Forecast: What's the Projected Valuation by 2029?
The market size for cardiovascular clinical trials is anticipated to experience significant expansion in the upcoming years. It is projected to reach $7.53 billion in 2029, with a compound annual growth rate (CAGR) of 7.0%. Several factors, such as an aging demographic, emerging markets, precision medicine, digital health advancements, and an emphasis on trials centered around patients, contribute to this growth in the forecasted period. The forecast period also expects to see a rise in partnerships, technological progress, product innovations, introduction of new products, and the market entry of generic combination drugs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cardiovascular-clinical-trials-global-market-report

What Are the Drivers Transforming the Cardiovascular Clinical Trials Market?
The cardiovascular clinical trials market is anticipated to expand due to the rising prevalence of cardiovascular diseases. These diseases encompass conditions that impact the heart and blood vessels, taking in heart failure, coronary artery disease, and strokes. A surge in cardiovascular diseases can be attributed to a range of factors including unhealthy eating habits, lack of exercise, smoking, obesity, hypertension, diabetes, and genetic factors. Cardiovascular clinical trials assist in the identification and validation of new pharmaceuticals that can more efficaciously manage risk factors such as high cholesterol, hypertension, and diabetes, which majorly contribute to cardiovascular diseases. For example, as per data released by the Minnesota Department of Health, a state health agency in the U.S, in September 2024, around 30% of adults in Minnesota, equating to close to 1.4 million persons, reported having high blood pressure in 2023. Additionally, according to the 2022 records, 14,225 residents died due to diseases related to hypertension, which amounted to nearly 28% of the total mortality rate in the state. Consequently, the escalating incidence of cardiovascular diseases is propelling the growth of the cardiovascular clinical trials market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15532&type=smp

What Long-Term Trends Will Define the Future of the Cardiovascular Clinical Trials Market?
To increase their distribution networks and reach more customers, major businesses in the cardiovascular clinical trials market are strategically partnering with contract research organizations (CROs). These partnerships are pivotal in the clinical research sector, facilitating cooperation between various companies to deliver specialized services for different aspects of clinical trials and research. For instance, in September 2023, Sweden-based biopharmaceutical firm Cereno Scientific AB teamed up with Clinical Trial Consultants (CTC), a full-service CRO also based in Sweden and specializing in clinical conduct. Together, they aim to initiate a Phase I research study for CS014, an agent designed to forestall arterial and venous thrombosis. CTC will furthermore offer assistance with the preparation processes for Phase I, such as the development of the study protocol and the application process for the clinical trial, expected to be undertaken in Sweden. Slated to commence in the first half of 2024, this first human Phase I trial marks a significant stride in progressing cardiovascular health research.

Which Segments in the Cardiovascular Clinical Trials Market Offer the Most Profit Potential?
The cardiovascular clinical trials market covered in this report is segmented -

1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Study Design: Interventional, Observational, Expanded Access
3) By Indication: Acute Coronary Syndrome, Coronary Artery Disease, Ischemic Heart Disease, Pulmonary Arterial Hypertension, Stroke, Cardiac Arrhythmias, Heart Failure, Other Indications

Subsegments:
1) By Phase I: First-in-Human Trials, Dose Escalation Studies, Safety and Tolerability Studies, Pharmacokinetics And Pharmacodynamics Studies
2) By Phase II: Efficacy Studies, Optimal Dosage And Administration Route Studies, Early Safety And Efficacy Trials, Biomarker Development Trials
3) By Phase III: Large-Scale Efficacy Trials, Randomized Controlled Trials (RCTs), Long-Term Safety And Efficacy Studies, Multicenter Trials
4) By Phase IV: Post-Marketing Surveillance, Long-Term Safety Studies, Real-World Evidence (RWE) Studies, Comparative Effectiveness Research

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15532&type=smp

Which Firms Dominate the Cardiovascular Clinical Trials Market by Market Share and Revenue in 2025?
Major companies operating in the cardiovascular clinical trials market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Baxter International Inc., IQVIA Holdings Inc., SGS S.A., PPD Inc., WuXi AppTec Co. Ltd., Caidya, Syneos Health Inc., Charles River Laboratories International Inc., Sanofi, ICON plc, Medpace Holdings Inc., Cardiovascular Clinical Sciences., ProRelix Services LLP, Worldwide Clinical Trials

Which Regions Offer the Highest Growth Potential in the Cardiovascular Clinical Trials Market?
North America was the largest region in the cardiovascular clinical trials market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15532

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.